Cognition, Stress Reaction
Conditions
Keywords
cognition, adult, prefrontal cortex, Transcranial Magnetic Stimulation, Stress, Psychological, memory, attention
Brief summary
The purpose of this study is to determine the most effective dose of brief, non-invasive brain stimulation (repetitive transcranial magnetic stimulation, rTMS) for improving cognitive functions such as attention and memory as well as to improve the ability to recover from stressful situations (stress resilience).
Detailed description
Repetitive transcranial magnetic stimulation (rTMS) works by rapidly turning a focused magnetic field on-and-off repeatedly over your head, which passes directly through your hair, scalp, and skull and onto your brain, and can temporarily increase brain activity under the magnetic field. Repetitive transcranial magnetic stimulation (rTMS) is an FDA approved treatment for depression, and is used commonly to treat people for their depression. The rTMS treatment regime used in this study is different from the FDA approved treatment because you will receive up to ten treatments per day over five days instead of the FDA approved rTMS treatment regime of 25 treatments over 25 days. This sort of accelerated or high dose protocol has been shown to be safe and effective in the treatment of depression. We are hoping to find out if this treatment can be used as a treatment for improving cognitive function and stress resilience.
Interventions
Device: Repetitive Transcranial Magnetic Stimulation (rTMS) MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.
Sponsors
Study design
Eligibility
Inclusion criteria
1. No history of mental or physical illness 2. No implanted metal in the body 3. College graduates (Associates degree or higher) 4. Negative urine pregnancy test, if female subject of childbearing potential 5. Able to read and understand questionnaires and informed consent
Exclusion criteria
1. Any current psychiatric diagnosis or current Clinical Global Impression ratings of psychiatric illness \> 1 2. Current physical illness 3. History of CNS disease, concussion, overnight hospitalization, tumors, seizures, meningitis, encephalitis, abnormal CT/MRI of the brain 4. Moderate to severe traumatic brain injury (TBI) 5. History of a continuing significant laboratory finding 6. Frequent or severe headaches 7. Any history of psychotropic medication prior to study enrollment 8. Females of childbearing potential who are pregnant (by urine HCG), nursing, or who are not using a reliable form of birth control. 9. active participation or plan for enrollment in another evidence-based clinical trial affecting psychosocial function 10. repeated abuse or dependence upon drugs (excluding nicotine and caffeine) 11. implanted devices/ferrous metal of any kind
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean Score of Neurocognitive Performance (Fluid Cognition) | Baseline (Day 1) | Participants would complete a computerized batteries (Penn Computerized Neuropsychological Battery and NIH Cognition Battery). Tasks would assess the following domains: information-processing speed, executive function, sustained attention/vigilance, verbal memory, working-memory capacity, inhibition/impulsivity, and sensorimotor function. This composite includes all the tests noted above that are fluid ability measures: Flanker, Dimensional Change Card Sort, Picture Sequence Memory, List Sorting and Pattern Comparison. This composite score is derived by averaging the standard scores of each of the measures, and then deriving standard scores based on this new distribution. Higher values (positive changes from baseline) indicate better performance. The T-score has a mean of 50 in the general population and a SD of 10. Scores higher than the mean indicate better performance. |
| Change From Baseline in Neurocognitive Performance at 1 Week Post Treatment (Fluid Cognition) | Post-treatment (within 1 week of completing rTMS) | Participants would complete a computerized batteries (Penn Computerized Neuropsychological Battery and NIH Cognition Battery). Tasks would assess the following domains: information-processing speed, executive function, sustained attention/vigilance, verbal memory, working-memory capacity, inhibition/impulsivity, and sensorimotor function. This composite includes all the tests noted above that are fluid ability measures: Flanker, Dimensional Change Card Sort, Picture Sequence Memory, List Sorting and Pattern Comparison. This composite score is derived by averaging the standard scores of each of the measures, and then deriving standard scores based on this new distribution. The T-score has a mean of 50 in the general population and a SD of 10. Scores higher than the mean indicate better performance. |
| Change From Baseline in Neurocognitive Performance at 1 Month Post Treatment (Fluid Cognition) | Post-treatment (within 1 month of completing rTMS) | Participants would complete a computerized batteries (Penn Computerized Neuropsychological Battery and NIH Cognition Battery). Tasks would assess the following domains: information-processing speed, executive function, sustained attention/vigilance, verbal memory, working-memory capacity, inhibition/impulsivity, and sensorimotor function. This composite includes all the tests noted above that are fluid ability measures: Flanker, Dimensional Change Card Sort, Picture Sequence Memory, List Sorting and Pattern Comparison. This composite score is derived by averaging the standard scores of each of the measures, and then deriving standard scores based on this new distribution. The T-score has a mean of 50 in the general population and a SD of 10. Scores higher than the mean indicate better performance. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mean Score of Neurocognitive Performance (WINSCAT Composite) | Baseline (Day 1) | The WINSCAT battery includes 5 subtests: Code Substitution (CDS), Code Substitution Delayed Recognition (CDD), Delayed Matching to Sample (MSP), Mathematical Processing (MTH), and Running Memory Continuous Performance (CPT). Each subtest produces a standardized score (range: 0-100). Composite score is the sum of all subtests (range: 0-500). Higher scores indicate better cognitive performance. Baseline scores reflect initial neurocognitive status. WINSCAT assesses attention, memory, visual processing, and executive function. |
| Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale | Baseline (Day 1) | Participants would complete a series of questionnaires Connor Davidson Resilience Scale is a self-reported scale consisting of 10-items measuring resilience. Respondents rate items on a 5-point Likert scale, ranging from 0 (not true at all) to 4 (true nearly all the time). Each item has a minimum score of 0 and a maximum score of 4. The minimum value is a 0 and the maximum value is a 100. A higher score indicates higher resilience, which indicates a better outcome. -Questions are rated on a scale from 0-4, where a higher score reflects greater resilience. |
| Mean Score of Neurocognitive Performance (Stress Total Score) | Baseline (Day 1) | is a 99-item self-report questionnaire assessing emotional and psychological symptoms across 18 subscales. For this outcome, a subset of items was used to assess stress resilience, likely drawn from the Well-Being or related subscales. Each item is rated on a 5-point Likert scale from 1 (Not at all) to 5 (Extremely). Scores were summed across selected items. Minimum possible score: 0 Maximum possible score: 15 Lower scores indicate greater resilience and better emotional functioning. Higher scores indicate greater symptom severity and worse outcomes. |
| Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-10 | Baseline (Day 1) | The investigators will use the Perceived Stress Scale 10 (PSS-10) to assess perceived stress using a 5-point Likert scale. Scoring Instructions: Total score is determined by adding together the scores of each of the four items. Questions 2 and 3 are reverse coded. Questions 1 and 4: 0 = Never; 1 = Almost never; 2 = Sometimes; 3 = Fairly often; 4 = Very often Questions 2 and 3: 4 = Never; 3 = Almost never; 2 = Sometimes; 1 = Fairly often; 0 = Very often. Scores range from 0 to 40 with higher scores indicating more stress. |
| Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II | Baseline (Day 1) | The Inventory of Depression and Anxiety Symptoms-II (IDAS-II) is a 99-item self-report questionnaire assessing emotional and psychological symptoms across 18 subscales. Each item is rated on a 5-point Likert scale from 1 (Not at all) to 5 (Extremely). In this study, a composite score was calculated by summing responses across multiple relevant subscales (e.g., Dysphoria, Panic, Insomnia, Well-Being) to assess overall emotional distress and stress resilience. Minimum possible score: 99 (if all items scored 1) Maximum possible score: 495 (if all items scored 5) Higher scores indicate greater symptom severity and worse outcomes. Lower scores reflect better emotional functioning and greater resilience. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Dose 1 All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is 5 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
rTMS: Device: Repetitive Transcranial Magnetic Stimulation (rTMS) MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex. | 4 |
| Dose 2 All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 2 is 10 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
rTMS: Device: Repetitive Transcranial Magnetic Stimulation (rTMS) MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex. | 4 |
| Dose 3 All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 3 is 15 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
rTMS: Device: Repetitive Transcranial Magnetic Stimulation (rTMS) MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex. | 4 |
| Dose 4 All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 4 is 20 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
rTMS: Device: Repetitive Transcranial Magnetic Stimulation (rTMS) MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex. | 4 |
| Dose 5 All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 5 is 25 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
rTMS: Device: Repetitive Transcranial Magnetic Stimulation (rTMS) MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex. | 4 |
| Dose 6 All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 6 is 30 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
rTMS: Device: Repetitive Transcranial Magnetic Stimulation (rTMS) MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex. | 4 |
| Dose 7 All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 7 is 35 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
rTMS: Device: Repetitive Transcranial Magnetic Stimulation (rTMS) MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex. | 4 |
| Dose 8 All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 8 is 40 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
rTMS: Device: Repetitive Transcranial Magnetic Stimulation (rTMS) MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex. | 3 |
| Dose 9 All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 9 is 45 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
rTMS: Device: Repetitive Transcranial Magnetic Stimulation (rTMS) MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex. | 3 |
| Dose 10 All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 10 is 50 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
rTMS: Device: Repetitive Transcranial Magnetic Stimulation (rTMS) MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex. | 4 |
| Total | 38 |
Baseline characteristics
| Characteristic | Total | Dose 2 | Dose 1 | Dose 3 | Dose 4 | Dose 5 | Dose 6 | Dose 7 | Dose 8 | Dose 9 | Dose 10 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 38 Participants | 4 Participants | 4 Participants | 4 Participants | 4 Participants | 4 Participants | 4 Participants | 4 Participants | 3 Participants | 3 Participants | 4 Participants |
| Race/Ethnicity, Customized African American | 5 Participants | 1 Participants | 1 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants |
| Race/Ethnicity, Customized Caucasian | 31 Participants | 3 Participants | 3 Participants | 4 Participants | 3 Participants | 4 Participants | 2 Participants | 3 Participants | 3 Participants | 2 Participants | 4 Participants |
| Race/Ethnicity, Customized Other-Egyptian | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Other-Vietnamese American | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Sex: Female, Male Female | 21 Participants | 3 Participants | 2 Participants | 2 Participants | 3 Participants | 2 Participants | 3 Participants | 2 Participants | 0 Participants | 2 Participants | 2 Participants |
| Sex: Female, Male Male | 17 Participants | 1 Participants | 2 Participants | 2 Participants | 1 Participants | 2 Participants | 1 Participants | 2 Participants | 3 Participants | 1 Participants | 2 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk | EG009 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 4 | 0 / 4 | 0 / 4 | 0 / 4 | 0 / 4 | 0 / 4 | 0 / 4 | 0 / 3 | 0 / 3 | 0 / 4 |
| other Total, other adverse events | 0 / 4 | 0 / 4 | 0 / 4 | 0 / 4 | 0 / 4 | 0 / 4 | 0 / 4 | 0 / 3 | 0 / 3 | 0 / 4 |
| serious Total, serious adverse events | 0 / 4 | 0 / 4 | 0 / 4 | 0 / 4 | 0 / 4 | 0 / 4 | 0 / 4 | 0 / 3 | 0 / 3 | 0 / 4 |
Outcome results
Change From Baseline in Neurocognitive Performance at 1 Month Post Treatment (Fluid Cognition)
Participants would complete a computerized batteries (Penn Computerized Neuropsychological Battery and NIH Cognition Battery). Tasks would assess the following domains: information-processing speed, executive function, sustained attention/vigilance, verbal memory, working-memory capacity, inhibition/impulsivity, and sensorimotor function. This composite includes all the tests noted above that are fluid ability measures: Flanker, Dimensional Change Card Sort, Picture Sequence Memory, List Sorting and Pattern Comparison. This composite score is derived by averaging the standard scores of each of the measures, and then deriving standard scores based on this new distribution. The T-score has a mean of 50 in the general population and a SD of 10. Scores higher than the mean indicate better performance.
Time frame: Post-treatment (within 1 month of completing rTMS)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Dose 1 | Change From Baseline in Neurocognitive Performance at 1 Month Post Treatment (Fluid Cognition) | 73.333 score on a scale | Standard Deviation 9.292 |
| Dose 2 | Change From Baseline in Neurocognitive Performance at 1 Month Post Treatment (Fluid Cognition) | 65.000 score on a scale | Standard Deviation 6.557 |
| Dose 3 | Change From Baseline in Neurocognitive Performance at 1 Month Post Treatment (Fluid Cognition) | 68.000 score on a scale | Standard Deviation 11.106 |
| Dose 4 | Change From Baseline in Neurocognitive Performance at 1 Month Post Treatment (Fluid Cognition) | 71.250 score on a scale | Standard Deviation 6.5 |
| Dose 5 | Change From Baseline in Neurocognitive Performance at 1 Month Post Treatment (Fluid Cognition) | 71.750 score on a scale | Standard Deviation 7.762 |
| Dose 6 | Change From Baseline in Neurocognitive Performance at 1 Month Post Treatment (Fluid Cognition) | 68.333 score on a scale | Standard Deviation 4.726 |
| Dose 7 | Change From Baseline in Neurocognitive Performance at 1 Month Post Treatment (Fluid Cognition) | 72.333 score on a scale | Standard Deviation 10.263 |
| Dose 8 | Change From Baseline in Neurocognitive Performance at 1 Month Post Treatment (Fluid Cognition) | 74.000 score on a scale | Standard Deviation 2.646 |
| Dose 9 | Change From Baseline in Neurocognitive Performance at 1 Month Post Treatment (Fluid Cognition) | 73.667 score on a scale | Standard Deviation 3.215 |
| Dose 10 | Change From Baseline in Neurocognitive Performance at 1 Month Post Treatment (Fluid Cognition) | 67.500 score on a scale | Standard Deviation 6.557 |
Change From Baseline in Neurocognitive Performance at 1 Week Post Treatment (Fluid Cognition)
Participants would complete a computerized batteries (Penn Computerized Neuropsychological Battery and NIH Cognition Battery). Tasks would assess the following domains: information-processing speed, executive function, sustained attention/vigilance, verbal memory, working-memory capacity, inhibition/impulsivity, and sensorimotor function. This composite includes all the tests noted above that are fluid ability measures: Flanker, Dimensional Change Card Sort, Picture Sequence Memory, List Sorting and Pattern Comparison. This composite score is derived by averaging the standard scores of each of the measures, and then deriving standard scores based on this new distribution. The T-score has a mean of 50 in the general population and a SD of 10. Scores higher than the mean indicate better performance.
Time frame: Post-treatment (within 1 week of completing rTMS)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Dose 1 | Change From Baseline in Neurocognitive Performance at 1 Week Post Treatment (Fluid Cognition) | 72.500 score on a scale | Standard Deviation 5.916 |
| Dose 2 | Change From Baseline in Neurocognitive Performance at 1 Week Post Treatment (Fluid Cognition) | 63.750 score on a scale | Standard Deviation 5.852 |
| Dose 3 | Change From Baseline in Neurocognitive Performance at 1 Week Post Treatment (Fluid Cognition) | 67.750 score on a scale | Standard Deviation 13.5 |
| Dose 4 | Change From Baseline in Neurocognitive Performance at 1 Week Post Treatment (Fluid Cognition) | 69.500 score on a scale | Standard Deviation 11.79 |
| Dose 5 | Change From Baseline in Neurocognitive Performance at 1 Week Post Treatment (Fluid Cognition) | 70.000 score on a scale | Standard Deviation 11.165 |
| Dose 6 | Change From Baseline in Neurocognitive Performance at 1 Week Post Treatment (Fluid Cognition) | 73.250 score on a scale | Standard Deviation 5.252 |
| Dose 7 | Change From Baseline in Neurocognitive Performance at 1 Week Post Treatment (Fluid Cognition) | 71.000 score on a scale | Standard Deviation 10.1 |
| Dose 8 | Change From Baseline in Neurocognitive Performance at 1 Week Post Treatment (Fluid Cognition) | 71.667 score on a scale | Standard Deviation 5.508 |
| Dose 9 | Change From Baseline in Neurocognitive Performance at 1 Week Post Treatment (Fluid Cognition) | 69.000 score on a scale | Standard Deviation 9.899 |
| Dose 10 | Change From Baseline in Neurocognitive Performance at 1 Week Post Treatment (Fluid Cognition) | 63.750 score on a scale | Standard Deviation 7.588 |
Mean Score of Neurocognitive Performance (Fluid Cognition)
Participants would complete a computerized batteries (Penn Computerized Neuropsychological Battery and NIH Cognition Battery). Tasks would assess the following domains: information-processing speed, executive function, sustained attention/vigilance, verbal memory, working-memory capacity, inhibition/impulsivity, and sensorimotor function. This composite includes all the tests noted above that are fluid ability measures: Flanker, Dimensional Change Card Sort, Picture Sequence Memory, List Sorting and Pattern Comparison. This composite score is derived by averaging the standard scores of each of the measures, and then deriving standard scores based on this new distribution. Higher values (positive changes from baseline) indicate better performance. The T-score has a mean of 50 in the general population and a SD of 10. Scores higher than the mean indicate better performance.
Time frame: Baseline (Day 1)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Dose 1 | Mean Score of Neurocognitive Performance (Fluid Cognition) | 63.500 score on a scale | Standard Deviation 5.447 |
| Dose 2 | Mean Score of Neurocognitive Performance (Fluid Cognition) | 50.250 score on a scale | Standard Deviation 10.079 |
| Dose 3 | Mean Score of Neurocognitive Performance (Fluid Cognition) | 59.750 score on a scale | Standard Deviation 13.598 |
| Dose 4 | Mean Score of Neurocognitive Performance (Fluid Cognition) | 57.250 score on a scale | Standard Deviation 13.15 |
| Dose 5 | Mean Score of Neurocognitive Performance (Fluid Cognition) | 60.500 score on a scale | Standard Deviation 12.819 |
| Dose 6 | Mean Score of Neurocognitive Performance (Fluid Cognition) | 65.250 score on a scale | Standard Deviation 5.795 |
| Dose 7 | Mean Score of Neurocognitive Performance (Fluid Cognition) | 58.250 score on a scale | Standard Deviation 9.777 |
| Dose 8 | Mean Score of Neurocognitive Performance (Fluid Cognition) | 61.000 score on a scale | Standard Deviation 3.464 |
| Dose 9 | Mean Score of Neurocognitive Performance (Fluid Cognition) | 70.333 score on a scale | Standard Deviation 9.866 |
| Dose 10 | Mean Score of Neurocognitive Performance (Fluid Cognition) | 58.250 score on a scale | Standard Deviation 4.856 |
Mean Score of Neurocognitive Performance (Stress Total Score)
is a 99-item self-report questionnaire assessing emotional and psychological symptoms across 18 subscales. For this outcome, a subset of items was used to assess stress resilience, likely drawn from the Well-Being or related subscales. Each item is rated on a 5-point Likert scale from 1 (Not at all) to 5 (Extremely). Scores were summed across selected items. Minimum possible score: 0 Maximum possible score: 15 Lower scores indicate greater resilience and better emotional functioning. Higher scores indicate greater symptom severity and worse outcomes.
Time frame: Post-treatment (within 1 month of completing rTMS)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Dose 1 | Mean Score of Neurocognitive Performance (Stress Total Score) | 13.333 score on a scale | Standard Deviation 3.055 |
| Dose 2 | Mean Score of Neurocognitive Performance (Stress Total Score) | 11.000 score on a scale | Standard Deviation 3.606 |
| Dose 3 | Mean Score of Neurocognitive Performance (Stress Total Score) | 11.000 score on a scale | Standard Deviation 3.367 |
| Dose 4 | Mean Score of Neurocognitive Performance (Stress Total Score) | 6.750 score on a scale | Standard Deviation 4.787 |
| Dose 5 | Mean Score of Neurocognitive Performance (Stress Total Score) | 5.250 score on a scale | Standard Deviation 2.217 |
| Dose 6 | Mean Score of Neurocognitive Performance (Stress Total Score) | 7.750 score on a scale | Standard Deviation 7.676 |
| Dose 7 | Mean Score of Neurocognitive Performance (Stress Total Score) | 8.667 score on a scale | Standard Deviation 6.028 |
| Dose 8 | Mean Score of Neurocognitive Performance (Stress Total Score) | 7.000 score on a scale | Standard Deviation 7 |
| Dose 9 | Mean Score of Neurocognitive Performance (Stress Total Score) | 13.667 score on a scale | Standard Deviation 10.017 |
| Dose 10 | Mean Score of Neurocognitive Performance (Stress Total Score) | 7.500 score on a scale | Standard Deviation 2.646 |
Mean Score of Neurocognitive Performance (Stress Total Score)
is a 99-item self-report questionnaire assessing emotional and psychological symptoms across 18 subscales. For this outcome, a subset of items was used to assess stress resilience, likely drawn from the Well-Being or related subscales. Each item is rated on a 5-point Likert scale from 1 (Not at all) to 5 (Extremely). Scores were summed across selected items. Minimum possible score: 0 Maximum possible score: 15 Lower scores indicate greater resilience and better emotional functioning. Higher scores indicate greater symptom severity and worse outcomes.
Time frame: Baseline (Day 1)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Dose 1 | Mean Score of Neurocognitive Performance (Stress Total Score) | 12.500 score on a scale | Standard Deviation 3.109 |
| Dose 2 | Mean Score of Neurocognitive Performance (Stress Total Score) | 11.250 score on a scale | Standard Deviation 6.702 |
| Dose 3 | Mean Score of Neurocognitive Performance (Stress Total Score) | 13.500 score on a scale | Standard Deviation 3.873 |
| Dose 4 | Mean Score of Neurocognitive Performance (Stress Total Score) | 9.750 score on a scale | Standard Deviation 4.856 |
| Dose 5 | Mean Score of Neurocognitive Performance (Stress Total Score) | 6.250 score on a scale | Standard Deviation 5.909 |
| Dose 6 | Mean Score of Neurocognitive Performance (Stress Total Score) | 9.750 score on a scale | Standard Deviation 6.602 |
| Dose 7 | Mean Score of Neurocognitive Performance (Stress Total Score) | 9.750 score on a scale | Standard Deviation 3.304 |
| Dose 8 | Mean Score of Neurocognitive Performance (Stress Total Score) | 7.000 score on a scale | Standard Deviation 7.937 |
| Dose 9 | Mean Score of Neurocognitive Performance (Stress Total Score) | 13.333 score on a scale | Standard Deviation 5.033 |
| Dose 10 | Mean Score of Neurocognitive Performance (Stress Total Score) | 11.250 score on a scale | Standard Deviation 6.397 |
Mean Score of Neurocognitive Performance (Stress Total Score)
is a 99-item self-report questionnaire assessing emotional and psychological symptoms across 18 subscales. For this outcome, a subset of items was used to assess stress resilience, likely drawn from the Well-Being or related subscales. Each item is rated on a 5-point Likert scale from 1 (Not at all) to 5 (Extremely). Scores were summed across selected items. Minimum possible score: 0 Maximum possible score: 15 Lower scores indicate greater resilience and better emotional functioning. Higher scores indicate greater symptom severity and worse outcomes.
Time frame: Post-treatment (within 1 week of completing rTMS)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Dose 1 | Mean Score of Neurocognitive Performance (Stress Total Score) | 15.500 score on a scale | Standard Deviation 4.655 |
| Dose 2 | Mean Score of Neurocognitive Performance (Stress Total Score) | 13.500 score on a scale | Standard Deviation 3.109 |
| Dose 3 | Mean Score of Neurocognitive Performance (Stress Total Score) | 11.500 score on a scale | Standard Deviation 6.351 |
| Dose 4 | Mean Score of Neurocognitive Performance (Stress Total Score) | 11.000 score on a scale | Standard Deviation 4.082 |
| Dose 5 | Mean Score of Neurocognitive Performance (Stress Total Score) | 6.750 score on a scale | Standard Deviation 4.573 |
| Dose 6 | Mean Score of Neurocognitive Performance (Stress Total Score) | 11.000 score on a scale | Standard Deviation 5.354 |
| Dose 7 | Mean Score of Neurocognitive Performance (Stress Total Score) | 11.500 score on a scale | Standard Deviation 7.55 |
| Dose 8 | Mean Score of Neurocognitive Performance (Stress Total Score) | 8.333 score on a scale | Standard Deviation 8.505 |
| Dose 9 | Mean Score of Neurocognitive Performance (Stress Total Score) | 14.000 score on a scale | Standard Deviation 7.211 |
| Dose 10 | Mean Score of Neurocognitive Performance (Stress Total Score) | 7.500 score on a scale | Standard Deviation 2.646 |
Mean Score of Neurocognitive Performance (WINSCAT Composite)
The WINSCAT battery includes 5 subtests: Code Substitution (CDS), Code Substitution Delayed Recognition (CDD), Delayed Matching to Sample (MSP), Mathematical Processing (MTH), and Running Memory Continuous Performance (CPT). Each subtest produces a standardized score (range: 0-100). Composite score is the sum of all subtests (range: 0-500). Higher scores indicate better cognitive performance. This measure reflects neurocognitive status 1 month after rTMS treatment. Scores are compared to baseline and 1-week post-treatment to assess sustained or enhanced cognitive improvement. WINSCAT evaluates attention, memory, visual processing, and executive function.
Time frame: Post-treatment (within 1 month of completing rTMS)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Dose 1 | Mean Score of Neurocognitive Performance (WINSCAT Composite) | 401.667 score on a scale | Standard Deviation 75.646 |
| Dose 2 | Mean Score of Neurocognitive Performance (WINSCAT Composite) | 380.333 score on a scale | Standard Deviation 42.618 |
| Dose 3 | Mean Score of Neurocognitive Performance (WINSCAT Composite) | 405.750 score on a scale | Standard Deviation 50.328 |
| Dose 4 | Mean Score of Neurocognitive Performance (WINSCAT Composite) | 414.750 score on a scale | Standard Deviation 95.73 |
| Dose 5 | Mean Score of Neurocognitive Performance (WINSCAT Composite) | 448.250 score on a scale | Standard Deviation 55.883 |
| Dose 6 | Mean Score of Neurocognitive Performance (WINSCAT Composite) | 424.500 score on a scale | Standard Deviation 40.673 |
| Dose 7 | Mean Score of Neurocognitive Performance (WINSCAT Composite) | 440.667 score on a scale | Standard Deviation 26.312 |
| Dose 8 | Mean Score of Neurocognitive Performance (WINSCAT Composite) | 431.667 score on a scale | Standard Deviation 36.638 |
| Dose 9 | Mean Score of Neurocognitive Performance (WINSCAT Composite) | 435.667 score on a scale | Standard Deviation 62.405 |
| Dose 10 | Mean Score of Neurocognitive Performance (WINSCAT Composite) | 429.250 score on a scale | Standard Deviation 20.271 |
Mean Score of Neurocognitive Performance (WINSCAT Composite)
The WINSCAT battery includes 5 subtests: Code Substitution (CDS), Code Substitution Delayed Recognition (CDD), Delayed Matching to Sample (MSP), Mathematical Processing (MTH), and Running Memory Continuous Performance (CPT). Each subtest produces a standardized score (range: 0-100). Composite score is the sum of all subtests (range: 0-500). Higher scores indicate better cognitive performance. Baseline scores reflect initial neurocognitive status. WINSCAT assesses attention, memory, visual processing, and executive function.
Time frame: Baseline (Day 1)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Dose 1 | Mean Score of Neurocognitive Performance (WINSCAT Composite) | 398.250 score on a scale | Standard Deviation 70.415 |
| Dose 2 | Mean Score of Neurocognitive Performance (WINSCAT Composite) | 302.500 score on a scale | Standard Deviation 61.278 |
| Dose 3 | Mean Score of Neurocognitive Performance (WINSCAT Composite) | 382.250 score on a scale | Standard Deviation 41.428 |
| Dose 4 | Mean Score of Neurocognitive Performance (WINSCAT Composite) | 366.250 score on a scale | Standard Deviation 98.524 |
| Dose 5 | Mean Score of Neurocognitive Performance (WINSCAT Composite) | 408.250 score on a scale | Standard Deviation 71.481 |
| Dose 6 | Mean Score of Neurocognitive Performance (WINSCAT Composite) | 367.750 score on a scale | Standard Deviation 30.511 |
| Dose 7 | Mean Score of Neurocognitive Performance (WINSCAT Composite) | 435.750 score on a scale | Standard Deviation 14.569 |
| Dose 8 | Mean Score of Neurocognitive Performance (WINSCAT Composite) | 382.000 score on a scale | Standard Deviation 77.544 |
| Dose 9 | Mean Score of Neurocognitive Performance (WINSCAT Composite) | 427.000 score on a scale | Standard Deviation 17.088 |
| Dose 10 | Mean Score of Neurocognitive Performance (WINSCAT Composite) | 400.750 score on a scale | Standard Deviation 54.414 |
Mean Score of Neurocognitive Performance (WINSCAT Composite)
The WINSCAT battery includes 5 subtests: Code Substitution (CDS), Code Substitution Delayed Recognition (CDD), Delayed Matching to Sample (MSP), Mathematical Processing (MTH), and Running Memory Continuous Performance (CPT). Each subtest produces a standardized score (range: 0-100). Composite score is the sum of all subtests (range: 0-500). Higher scores indicate better cognitive performance. This measure reflects post-treatment neurocognitive status following rTMS. Scores are compared to baseline to assess improvement. WINSCAT evaluates attention, memory, visual processing, and executive function.
Time frame: Post-treatment (within 1 week of completing rTMS)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Dose 1 | Mean Score of Neurocognitive Performance (WINSCAT Composite) | 406.750 score on a scale | Standard Deviation 76.129 |
| Dose 2 | Mean Score of Neurocognitive Performance (WINSCAT Composite) | 321.250 score on a scale | Standard Deviation 28.028 |
| Dose 3 | Mean Score of Neurocognitive Performance (WINSCAT Composite) | 388.250 score on a scale | Standard Deviation 31.795 |
| Dose 4 | Mean Score of Neurocognitive Performance (WINSCAT Composite) | 403.250 score on a scale | Standard Deviation 74.813 |
| Dose 5 | Mean Score of Neurocognitive Performance (WINSCAT Composite) | 445.000 score on a scale | Standard Deviation 94.278 |
| Dose 6 | Mean Score of Neurocognitive Performance (WINSCAT Composite) | 370.250 score on a scale | Standard Deviation 18.554 |
| Dose 7 | Mean Score of Neurocognitive Performance (WINSCAT Composite) | 459.000 score on a scale | Standard Deviation 46.819 |
| Dose 8 | Mean Score of Neurocognitive Performance (WINSCAT Composite) | 398.000 score on a scale | Standard Deviation 11.358 |
| Dose 9 | Mean Score of Neurocognitive Performance (WINSCAT Composite) | 503.667 score on a scale | Standard Deviation 15.275 |
| Dose 10 | Mean Score of Neurocognitive Performance (WINSCAT Composite) | 449.000 score on a scale | Standard Deviation 46.275 |
Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale
The Connor Davidson Resilience Scale (CD-RISC 10) is a unidimensional self-reported scale consisting of 10-items measuring resilience. Respondents rate items on a 5-point Likert scale, ranging from 0 (not true at all) to 4 (true nearly all the time). Each item has a minimum score of 0 and a maximum score of 4. The minimum value is a 0 and the maximum value is a 100. A higher score indicates higher resilience, which indicates a better outcome.
Time frame: Post-treatment (within 1 week of completing rTMS)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Dose 1 | Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale | 72.000 score on a scale | Standard Deviation 11.804 |
| Dose 2 | Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale | 70.750 score on a scale | Standard Deviation 7.848 |
| Dose 3 | Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale | 76.000 score on a scale | Standard Deviation 16.693 |
| Dose 4 | Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale | 79.500 score on a scale | Standard Deviation 9.678 |
| Dose 5 | Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale | 80.000 score on a scale | Standard Deviation 4.32 |
| Dose 6 | Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale | 75.000 score on a scale | Standard Deviation 7.024 |
| Dose 7 | Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale | 84.000 score on a scale | Standard Deviation 9.592 |
| Dose 8 | Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale | 78.333 score on a scale | Standard Deviation 15.044 |
| Dose 9 | Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale | 69.000 score on a scale | Standard Deviation 19.157 |
| Dose 10 | Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale | 73.000 score on a scale | Standard Deviation 7.958 |
Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale
The Connor Davidson Resilience Scale (CD-RISC 10) is a unidimensional self-reported scale consisting of 10-items measuring resilience. Respondents rate items on a 5-point Likert scale, ranging from 0 (not true at all) to 4 (true nearly all the time). Each item has a minimum score of 0 and a maximum score of 4. The minimum value is a 0 and the maximum value is a 100. A higher score indicates higher resilience, which indicates a better outcome.
Time frame: Post-treatment (within 1 month of completing rTMS)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Dose 1 | Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale | 69.000 score on a scale | Standard Deviation 9.695 |
| Dose 2 | Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale | 68.000 score on a scale | Standard Deviation 17.795 |
| Dose 3 | Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale | 80.000 score on a scale | Standard Deviation 13.241 |
| Dose 4 | Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale | 82.000 score on a scale | Standard Deviation 12.702 |
| Dose 5 | Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale | 84.500 score on a scale | Standard Deviation 9.183 |
| Dose 6 | Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale | 73.000 score on a scale | Standard Deviation 7.303 |
| Dose 7 | Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale | 81.500 score on a scale | Standard Deviation 10.755 |
| Dose 8 | Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale | 80.667 score on a scale | Standard Deviation 16.042 |
| Dose 9 | Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale | 68.667 score on a scale | Standard Deviation 22.03 |
| Dose 10 | Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale | 71.500 score on a scale | Standard Deviation 5.196 |
Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale
Participants would complete a series of questionnaires Connor Davidson Resilience Scale is a self-reported scale consisting of 10-items measuring resilience. Respondents rate items on a 5-point Likert scale, ranging from 0 (not true at all) to 4 (true nearly all the time). Each item has a minimum score of 0 and a maximum score of 4. The minimum value is a 0 and the maximum value is a 100. A higher score indicates higher resilience, which indicates a better outcome. -Questions are rated on a scale from 0-4, where a higher score reflects greater resilience.
Time frame: Baseline (Day 1)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Dose 1 | Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale | 70.750 score on a scale | Standard Deviation 10.079 |
| Dose 2 | Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale | 74.250 score on a scale | Standard Deviation 12.339 |
| Dose 3 | Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale | 75.250 score on a scale | Standard Deviation 12.842 |
| Dose 4 | Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale | 80.000 score on a scale | Standard Deviation 10.801 |
| Dose 5 | Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale | 83.250 score on a scale | Standard Deviation 7.274 |
| Dose 6 | Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale | 72.750 score on a scale | Standard Deviation 9.708 |
| Dose 7 | Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale | 77.500 score on a scale | Standard Deviation 5.447 |
| Dose 8 | Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale | 85.333 score on a scale | Standard Deviation 11.06 |
| Dose 9 | Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale | 69.333 score on a scale | Standard Deviation 19.63 |
| Dose 10 | Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale | 74.250 score on a scale | Standard Deviation 2.986 |
Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II
The Inventory of Depression and Anxiety Symptoms-II (IDAS-II) is a 99-item self-report questionnaire assessing emotional and psychological symptoms across 18 subscales. Each item is rated on a 5-point Likert scale from 1 (Not at all) to 5 (Extremely). In this study, a composite score was calculated by summing responses across multiple relevant subscales (e.g., Dysphoria, Panic, Insomnia, Well-Being) to assess overall emotional distress and stress resilience. Minimum possible score: 99 Maximum possible score: 495 Higher scores indicate greater symptom severity and worse outcomes. Lower scores reflect better emotional functioning and greater resilience.
Time frame: Post-treatment (within 1 week of completing rTMS)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Dose 1 | Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II | 142.750 score on a scale | Standard Deviation 9.5 |
| Dose 2 | Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II | 140.250 score on a scale | Standard Deviation 12.5 |
| Dose 3 | Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II | 140.750 score on a scale | Standard Deviation 21.391 |
| Dose 4 | Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II | 128.500 score on a scale | Standard Deviation 14.617 |
| Dose 5 | Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II | 125.250 score on a scale | Standard Deviation 4.349 |
| Dose 6 | Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II | 142.000 score on a scale | Standard Deviation 22.672 |
| Dose 7 | Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II | 135.750 score on a scale | Standard Deviation 12.258 |
| Dose 8 | Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II | 140.667 score on a scale | Standard Deviation 24.786 |
| Dose 9 | Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II | 133.333 score on a scale | Standard Deviation 11.06 |
| Dose 10 | Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II | 136.500 score on a scale | Standard Deviation 18.083 |
Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II
The Inventory of Depression and Anxiety Symptoms-II (IDAS-II) is a 99-item self-report questionnaire assessing emotional and psychological symptoms across 18 subscales. Each item is rated on a 5-point Likert scale from 1 (Not at all) to 5 (Extremely). In this study, a composite score was calculated by summing responses across multiple relevant subscales (e.g., Dysphoria, Panic, Insomnia, Well-Being) to assess overall emotional distress and stress resilience. Minimum possible score: 99 (if all items scored 1) Maximum possible score: 495 (if all items scored 5) Higher scores indicate greater symptom severity and worse outcomes. Lower scores reflect better emotional functioning and greater resilience.
Time frame: Baseline (Day 1)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Dose 1 | Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II | 136.250 score on a scale | Standard Deviation 9.032 |
| Dose 2 | Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II | 142.750 score on a scale | Standard Deviation 18.209 |
| Dose 3 | Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II | 144.500 score on a scale | Standard Deviation 12.124 |
| Dose 4 | Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II | 129.000 score on a scale | Standard Deviation 10.52 |
| Dose 5 | Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II | 127.750 score on a scale | Standard Deviation 4.573 |
| Dose 6 | Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II | 167.250 score on a scale | Standard Deviation 47.594 |
| Dose 7 | Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II | 133.500 score on a scale | Standard Deviation 14.364 |
| Dose 8 | Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II | 140.000 score on a scale | Standard Deviation 22.65 |
| Dose 9 | Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II | 136.667 score on a scale | Standard Deviation 17.388 |
| Dose 10 | Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II | 147.000 score on a scale | Standard Deviation 25.534 |
Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II
The Inventory of Depression and Anxiety Symptoms-II (IDAS-II) is a 99-item self-report questionnaire assessing emotional and psychological symptoms across 18 subscales. Each item is rated on a 5-point Likert scale from 1 (Not at all) to 5 (Extremely). In this study, a composite score was calculated by summing responses across multiple relevant subscales (e.g., Dysphoria, Panic, Insomnia, Well-Being) to assess overall emotional distress and stress resilience. Minimum possible score: 99 Maximum possible score: 495 Higher scores indicate greater symptom severity and worse outcomes. Lower scores reflect better emotional functioning and greater resilience.
Time frame: Post-treatment (within 1 month of completing rTMS)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Dose 1 | Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II | 140.250 score on a scale | Standard Deviation 11.295 |
| Dose 2 | Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II | 138.500 score on a scale | Standard Deviation 17.311 |
| Dose 3 | Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II | 142.750 score on a scale | Standard Deviation 14.175 |
| Dose 4 | Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II | 127.000 score on a scale | Standard Deviation 10.551 |
| Dose 5 | Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II | 122.500 score on a scale | Standard Deviation 3.697 |
| Dose 6 | Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II | 150.750 score on a scale | Standard Deviation 31.879 |
| Dose 7 | Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II | 134.250 score on a scale | Standard Deviation 14.818 |
| Dose 8 | Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II | 139.667 score on a scale | Standard Deviation 21.127 |
| Dose 9 | Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II | 128.667 score on a scale | Standard Deviation 15.631 |
| Dose 10 | Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II | 136.000 score on a scale | Standard Deviation 15.1 |
Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-10
The investigators will use the Perceived Stress Scale 10 (PSS-10) to assess perceived stress using a 5-point Likert scale. Scoring Instructions: Total score is determined by adding together the scores of each of the four items. Questions 2 and 3 are reverse coded. Questions 1 and 4: 0 = Never; 1 = Almost never; 2 = Sometimes; 3 = Fairly often; 4 = Very often Questions 2 and 3: 4 = Never; 3 = Almost never; 2 = Sometimes; 1 = Fairly often; 0 = Very often. Scores range from 0 to 40 with higher scores indicating more stress.
Time frame: Post-treatment (within 1 month of completing rTMS)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Dose 1 | Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-10 | 13.000 score on a scale | Standard Deviation 2.582 |
| Dose 2 | Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-10 | 12.750 score on a scale | Standard Deviation 2.986 |
| Dose 3 | Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-10 | 8.250 score on a scale | Standard Deviation 4.031 |
| Dose 4 | Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-10 | 6.750 score on a scale | Standard Deviation 4.787 |
| Dose 5 | Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-10 | 5.250 score on a scale | Standard Deviation 2.217 |
| Dose 6 | Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-10 | 10.500 score on a scale | Standard Deviation 6.856 |
| Dose 7 | Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-10 | 9.250 score on a scale | Standard Deviation 3.862 |
| Dose 8 | Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-10 | 5.667 score on a scale | Standard Deviation 7.371 |
| Dose 9 | Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-10 | 13.000 score on a scale | Standard Deviation 11 |
| Dose 10 | Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-10 | 7.500 score on a scale | Standard Deviation 2.646 |
Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-10
The investigators will use the Perceived Stress Scale 10 (PSS-10) to assess perceived stress using a 5-point Likert scale. Scoring Instructions: Total score is determined by adding together the scores of each of the four items. Questions 2 and 3 are reverse coded. Questions 1 and 4: 0 = Never; 1 = Almost never; 2 = Sometimes; 3 = Fairly often; 4 = Very often Questions 2 and 3: 4 = Never; 3 = Almost never; 2 = Sometimes; 1 = Fairly often; 0 = Very often. Scores range from 0 to 40 with higher scores indicating more stress.
Time frame: Post-treatment (within 1 week of completing rTMS)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Dose 1 | Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-10 | 15.500 score on a scale | Standard Deviation 4.655 |
| Dose 2 | Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-10 | 14.000 score on a scale | Standard Deviation 2.449 |
| Dose 3 | Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-10 | 10.000 score on a scale | Standard Deviation 6.88 |
| Dose 4 | Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-10 | 11.000 score on a scale | Standard Deviation 4.082 |
| Dose 5 | Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-10 | 6.750 score on a scale | Standard Deviation 4.573 |
| Dose 6 | Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-10 | 12.750 score on a scale | Standard Deviation 3.594 |
| Dose 7 | Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-10 | 6.750 score on a scale | Standard Deviation 3.594 |
| Dose 8 | Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-10 | 9.667 score on a scale | Standard Deviation 7.234 |
| Dose 9 | Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-10 | 13.667 score on a scale | Standard Deviation 7.767 |
| Dose 10 | Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-10 | 7.500 score on a scale | Standard Deviation 2.646 |
Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-10
The investigators will use the Perceived Stress Scale 10 (PSS-10) to assess perceived stress using a 5-point Likert scale. Scoring Instructions: Total score is determined by adding together the scores of each of the four items. Questions 2 and 3 are reverse coded. Questions 1 and 4: 0 = Never; 1 = Almost never; 2 = Sometimes; 3 = Fairly often; 4 = Very often Questions 2 and 3: 4 = Never; 3 = Almost never; 2 = Sometimes; 1 = Fairly often; 0 = Very often. Scores range from 0 to 40 with higher scores indicating more stress.
Time frame: Baseline (Day 1)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Dose 1 | Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-10 | 12.500 score on a scale | Standard Deviation 3.109 |
| Dose 2 | Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-10 | 12.500 score on a scale | Standard Deviation 5.508 |
| Dose 3 | Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-10 | 12.500 score on a scale | Standard Deviation 4.796 |
| Dose 4 | Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-10 | 9.750 score on a scale | Standard Deviation 4.856 |
| Dose 5 | Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-10 | 6.250 score on a scale | Standard Deviation 5.909 |
| Dose 6 | Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-10 | 11.500 score on a scale | Standard Deviation 5.802 |
| Dose 7 | Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-10 | 7.250 score on a scale | Standard Deviation 5.56 |
| Dose 8 | Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-10 | 8.667 score on a scale | Standard Deviation 6.429 |
| Dose 9 | Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-10 | 12.333 score on a scale | Standard Deviation 6.658 |
| Dose 10 | Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-10 | 11.250 score on a scale | Standard Deviation 6.397 |